Key points for investors:
- Revenue and guidance: CareCloud reported Q1 2026 revenue of $31.3M, up 13% year-over-year. Management reaffirmed full-year 2026 guidance: revenue $128M–$132M, adjusted EBITDA $29M–$31M, and GAAP EPS $0.20–$0.23 (more than 100% above 2025 EPS).
- Profitability and cash flow: GAAP net income was $0.9M (eighth consecutive quarter of positive GAAP net income). Adjusted EBITDA was $5.4M (17% of revenue). Free cash flow was $2.4M in Q1. Management emphasizes non-GAAP metrics as the cleaner read on operating performance while absorbing acquisition-related charges.
- Capital structure simplification: In April the company closed a $50M credit facility ( $40M term loan + $10M revolver) and established an ATM program. The Board elected to redeem 100% of outstanding Series B preferred stock (redemption scheduled May 15) and has prefunded approximately $41.6M. Management positions this as removing a long-standing preferred equity overhang, lowering WACC, and broadening appeal to institutional investors without diluting common shareholders.
- M&A and integration: Integration of 2025 acquisitions (notably Medsphere and MAP App) is underway. Medsphere brings inpatient/hospital assets (Wellsoft EDIS, CareView inpatient EHR, ChartLogic, Marketware, supply chain and managed IT), expanding addressable market beyond ambulatory to the care continuum.
- AI traction and strategy: CareCloud markets AI along three coordinated tracks — (1) back-end AI to optimize internal RCM and operations, (2) embedding AI into existing customer-facing products, and (3) new stand-alone AI products. StratusAI Desk Agent (Front Desk) reached full commercial release and is scaling; management reports it now handles ~75% of inbound calls for early adopters. cirrusAI Notes (ambient documentation) and AI prior-authorization and AI-assisted coding are in development or piloting. Management emphasizes cross-sell into existing base and Medsphere customers as a key revenue lever.
- Operational cadence and margin progression: Q1 is seasonally the weakest quarter; management expects margins to improve as Medsphere integration, duplication elimination and amortization run-off progress through 2026 and into 2027. Free cash flow generation supports the Series B redemption and future M&A optionality.
- Risks/near-term headwinds: Elevated amortization and integration/transitional costs from acquisitions compressed GAAP net income and free cash flow in Q1; execution risk remains for integrating Medsphere and scaling AI products; continued seasonality in Q1. Management notes conservative posture on ATM use and will deploy equity only for clearly accretive uses.
Overall investor takeaway: The company delivered top-line growth, is generating positive cash flow, has materially simplified its capital structure, and is positioning AI and cross-sell from recent acquisitions as the primary drivers of scaled revenue and margin expansion through 2026 and beyond. Execution on integrations and commercial scaling of AI products are the key items to monitor.
Sign In
Buy CCLDO
